Telesis Bio to Present at the Cowen 43rd Annual Healthcare Conference

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) — Telesis Bio Inc. (NASDAQ: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that Todd R. Nelson, PhD, the company’s chief executive officer, will participate in a fireside chat with Steven Mah at the 43rd Annual Cowen Healthcare Conference on Monday, March 6th at 12:50 PM Eastern Time/ 9:50AM Pacific Time. Additionally, Todd will participate in a ‘Synthetic Biology Enabling Technologies Panel’ on Tuesday, March 7th at 4:40pm Eastern time / 1:40 pm Pacific Time.

The fireside chat and panel discussion will both be webcast live and can be accessed through a link on the investors section of Telesis Bio’s investor relations website at An archived replay of each webcast will be available for 30 days following the event.

About Telesis Bio
Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit

Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

Jen Carroll
Vice President of Investor Relations

error: Content is protected !!